Carbone et al. [109] showed that stage IV or recurrent NSCLC patients with both high tumor-mutation burden and ≥50% PD-L1 expression level had a better response to nivolumab than those with only one or neither of these biomarkers. Here, CD274 is linked to non-small cell lung carcinoma.